# STAR-EV (NCT06394570)

> Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: enfortumab vedotin
- Indication: localized bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06394570
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: University of Texas Southwestern Medical Center
- Conditions: Bladder Cancer
- Interventions: Enfortumab vedotin
- Enrollment: 19
- Primary outcome: Maximum Tolerated Dose (MTD) Regimen
- Primary outcome: Pathologic Complete response rate at radical cystectomy

## Questions raised in the commentary

_Automated from the 11 newest of 16 indexed sources (Jul 2024 – Sep 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether EV and radiation can support bladder-preserving approaches
- Whether EV and radiation can increase pathologic complete response rates
- How tolerable EV and radiation are together

## Indexed commentary on STAR-EV so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- YouTube: 3
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=star-ev-nct06394570

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06394570", "email": "<work email>"}; the inbox owner confirms by the emailed link.